

From: [REDACTED] on behalf of  
[REDACTED]  
Sent: 26 September 2011 07:41  
To: TA Comm B  
Cc: [REDACTED]  
Subject: NICE - Colorectal cancer (metastatic) 2nd line - cetuximab,  
bevacizumab  
and panitumumab (review)- ACD and Evaluation Report:

Dear NICE

Thank you for the opportunity to comment on the appraisal consultation document and evaluation report for the above multiple technology appraisal.

I wish to confirm that the Department of Health has no substantive comments to make regarding this consultation.

Many thanks and best wishes

[REDACTED]  
NICE Sponsor Team  
Department of Health

- - Disclaimer - -

This e-mail and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this e-mail is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received.

Incoming and outgoing e-mail messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's e-mail policy click here <http://www.dh.gov.uk/terms>

The original of this email was scanned for viruses by the Government Secure Intranet virus scanning service supplied by Cable&Wireless Worldwide in partnership with MessageLabs.  
(CCTM Certificate Number 2009/09/0052.) On leaving the GSi this email was certified virus free.  
Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.

---

Delivered via MessageLabs

